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Abstract. The production of genetically modified (GM) animals is an emerging 
technique that could potentially impact the livestock and pharmaceutical industries. 
Currently, food products derived from GM animals have not yet entered the market 
whilst two pharmaceutical products have. The objective of this paper is twofold: first 
it aims to explore the socio-economic drivers affecting the use of GM animals and, 
second, to review the risks and benefits from the point of view of the life sciences. A 
scoping study was conducted to assess research relevant to understanding the main 
drivers influencing the adoption of GM applications and their potential risks and ben-
efits. Public and producers’ acceptance, public policies, human health, animal welfare, 
environmental impact and sustainability are considered as the main factors affecting 
the application of GM animal techniques in livestock and pharmaceutical chains. 
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1. Introduction
The production of genetically modified (GM) animals is an emerging technique that 
could potentially impact the livestock and pharmaceutical industries. Most GM animals 
have been developed for research in private or University laboratories; rodents, but also 
rabbits and pigs, are genetically modified to study action and function of gene mecha-
nisms. Apart from those GM animals developed for recreational purposes (e.g., the first 
GM animal commercialized was GloFish®, a GM Zebra fish with a fluorescent gene to 
glow in the dark under UV light), some GM animals are also being produced to improve 
livestock production, such as those developed to increase growth, to be disease resistant 
or to increase the quality of their products (meat, milk, etc.). Other applications, such as 
EnviropigTM, were created to reduce the environmental impact of farming (e.g., reduc-
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ing phosphorus pollution). Finally, genetic engineering can be used for bio-medical and 
human health applications, like GM livestock (cows, goats, sheep, pigs, chickens or rab-
bits) developed for producing pharmaceutical proteins from milk, egg white or other flu-
ids (e.g., blood), human antibodies, animal tissue or organs for use in human transplants, 
or xenotransplantation (Houdebine, 2009; Laible, 2009; Murray et al., 2010; Vàzquez-Salat 
et al., 2012). 
Although the economic analyses of potential costs and benefits of GM crops are wide-
ly described and used, there is little analysis of GM applications in the animal and phar-
maceutical chains. This is because genetic modification of animals has proceeded much 
slower than crops, for a variety of reasons, such as socio-economic, technical, human 
health, environmental and animal welfare factors. This paper examines the main drivers 
affecting the development and adoption of transgenic animals from a socio-economic and 
life science point of view. A scoping study was conducted to assess research relevant to 
understanding the main drivers influencing the adoption of GM applications.
Europe has had a leading role in the development of cloned and GM animals 
throughout the ‘90s. Notable examples include Dolly, the sheep that was the first animal 
created by cloning through transfer of a cell nucleus from a differentiated cell to an egg 
cell at the Roslin Institute in Scotland. Another example is Herman the bull, developed 
by the Dutch biotechnology company Gene Pharming Europe. Genetic modification was 
applied so that subsequent generations of female offspring would produce the protein 
lactoferrin through their milk, which can be used for food, nutraceutical, and pharmaceu-
tical purposes. Other experimental animals have been developed at European institutions, 
including genetically modified fish and chicken, with specific advantages and benefits to 
food production and other areas of application.
Despite considerable European innovations occurring in the area of GM animal tech-
nology, many of the current activities in the field of GM food animals take place outside 
the EU, in particular regions like the Far East, North and South America, and Australia-
New Zealand. It can be envisaged that some of these animals will possibly find their way 
into the European food supply chain through imports from overseas, in particular given 
that the EU is the world’s largest international trading block for food commodities.
In a more general sense, improvements in animal biotechnology (including but not 
limited to genetic modification of animals) are expected to result in economic benefits 
for farmers, processors and consumers. For instance, the development of GM fish species 
growing faster than non-GM ones is expected to reduce farming costs, e.g. feeding costs, 
while providing economic advantages for consumers in terms of lower prices (Menozzi 
et al., 2012). However, the distribution of these benefits depends on many factors like the 
type of technology (cost reducing or quality enhancing applications), market structure and 
competitiveness (concentration ratio, suppliers’ market power, etc.), information transpar-
ency (labelling and traceability programs, etc.), price elasticity, consumer acceptance, etc. 
Besides the direct economic effects, other externalities should also be considered in the 
overall economic evaluation. In particular, transgenic animals could provide substantial 
benefits to consumers in the form of safer food produced by healthier livestock, improved 
products including food with additional health benefits, and, in a more general sense, a 
cleaner environment through reduction of the environmental footprint of livestock farm-
ing (Laible, 2009). On the other hand, the application of animal biotechnology should be 
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properly controlled so as to prevent unintended environmental damage or increased risks 
to human health, as well as animal health and welfare. 
The objective of this paper is twofold: first it aims to provide insight into the socio-
economic drivers affecting the adoption of genetically modified (GM) animals in the food 
and pharmaceutical production chain (feed industry, breeding industry, primary sector, 
processing industry, and pharmaceutical industry). Second, it aims to review the risks 
and benefits from the point of view of the life sciences on issues like public health, animal 
health, animal welfare, environmental safety, sustainability, and agro-biodiversity. 
2. Material and Methods
Scoping studies aim to map rapidly the key concepts underpinning a research area 
and the main sources and types of evidence available (Arksey and O’Malley, 2005). Scop-
ing study guidelines have been developed to provide suggestions on how to identify rel-
evant papers (keywords, journals, web sources, etc.) for the socio-economic dimensions. 
Strict limitations on the use of search terms were avoided in these guidelines in order to 
identify relevant studies more clearly and study a selection at the outset and reporting 
stages. The process is not linear but iterative, requiring researchers to engage with each 
stage using reflection and, where necessary, to repeat steps to ensure that the literature 
was covered comprehensively.
The kind of terms that it was appropriate to search for was a key question for which 
all partners involved in the scoping study were asked to provide feedback. An initial list 
was provided as suggestions (Table 1), and new terms were added iteratively. 
Table 1. Keywords applied in the socio-economic search
Biotechnologies-related 
keywords
Methods-related  
keywords
Animals-related  
keywords
Use-related  
keywords
GM animals
GE animals
Transgenic animals
Clone 
GM food 
Traceability
Labelling
Identity preservation
Animal welfare 
Intellectual property 
rights
Stem cell
DNA 
Nucleus transfer
Biotech 
Genetic trait
Revenue
Cost, Benefit 
Price 
Economic effects
Cost-benefit analysis
Supply chain analysis
Willingness to pay
Added value
Food safety costs
Livestock economics
Net present value
Fish, Salmon, Carp, 
Tilapia
Pig, Sow, Swine
Sheep, Goat
Cow
Horse
Rabbit
Chicken
Bees
Food
Meat
Feed
Milk 
Pharmaceutical
Vaccine
Medical
Nutraceutical
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Several sources were considered in the analysis of the literature: electronic databases, 
reference lists, key journals and existing networks. The search strategy for electronic data-
bases (e.g. internet, CD-Rom, etc.) was developed from the research questions and defini-
tions of keywords and key concepts. It was important to check the reference lists and bibli-
ographies of studies found through the database searches to ensure they had been included 
in the scoping exercise. Another important step was the hand-searching of key journals; 
this helped to identify studies missed in database and reference list searches. Finally exist-
ing knowledge and networks could generate information about research. Contacting rel-
evant national or local organizations working in the field, EU projects and/or EU support 
researches with a view to hand-searching libraries and/or identifying unpublished work 
thus improved the analysis. Papers in English were preferred in the study; however, rele-
vant publications in other languages (e.g., Italian, Dutch, Spanish, etc.) were included in 
the research as well, provided there was an abstract in English covering the main informa-
tion included in the paper (subject, method applied, main results, etc.) or, alternatively, the 
main information had been translated into English for charting and reporting.
A “data charting form” was defined to collect and standardize all the information of 
the relevant papers. This form included general information about each study (e.g., year, 
aim of the study, source, etc.) and specific information (e.g., genetic modification, eco-
nomic effects, governance issues, methodology applied, main results, factors affecting 
the adoption of GM technologies, geographical location, outcome measures, data source, 
secondary results, etc.). In this way, the main characteristics of each study analyzed were 
shown in the form of a table or graph. These data formed the basis of the analysis. A total 
of 145 studies were collected from different sources.
3. Socio-economic factors affecting the introduction of GM animals
A third of the selected studies involved food chains and only in a relatively smaller 
proportion pharmaceutical chains (30%); about a half of the studies were reviews of trans-
genic applications and only one third empirical or econometric analysis. This shows the 
large number of reviews about potential applications of GM animals, rather than actual 
economic data. Many studies were published between 2002 and 2003 (30%), as well as 
in more recent years (25% after 2007). The type of animals involved was mostly bovine 
(44% of the studies), fish (30%) and swine (30%), showing a marked interest of research 
in these species. 
The review of methods to evaluate the economics of GM animals shows that, 
although there is great potential of GM applications to improve the performance of ani-
mal production chains and pharmaceutical products in theory, the applications ready for 
the market are very limited (Mora et al., 2011). Empirical research on economic factors, 
such as costs and benefits, affecting the introduction of GM applications in animal and 
pharmaceutical products compared to GM crop products is substantially lacking. For 
GM applications in animals, most of the economic analyses are focused on GM applica-
tions related to introduction of GM hormones or GM vaccines in animals. The economic 
analysis of GM applications in animals themselves (e.g. introducing foreign DNA into ger-
mline) are lacking to a great extent. Besides, most of the studies are not at the chain level, 
but at the farm or laboratory level. A wide variety of methods and techniques are used to 
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analyze the economic advantages and disadvantages of GM applications including quanti-
tative economic models, scenario analysis with simulation models, econometric analysis, 
and qualitative telephone interviews.
From the literature studied, the main factors affecting the (future) application of GM 
animals techniques to livestock and pharmaceutical chains range from public and pro-
ducers’ acceptance to public policies. Other factors, such as environmental sustainability, 
human health effects, animal welfare and ethical concerns are also involved and will be 
analysed in the following sections.
3.1 Public acceptance
Public acceptance is generally considered as a “condicio sine qua non” for any devel-
opment of transgenic animals in food and pharmaceutical chains. The uncertainty of con-
sumers’ reaction is the largest issue in assessing the potential of animal biotechnologies 
worldwide (Caswell et al., 2003). The framework suggested for adopting technology, there-
fore, takes the consumer as a starting point. Consumers’ attitude (positive vs. negative) 
and concerns (health, food safety, unnaturalness, ethical, environmental, animal health 
and welfare, etc.) are fundamental factors to understanding GM adoption and public per-
ceptions of GM technology. These issues have been the focus of several studies (Novo-
selova et al., 2007; Frewer et al., 2011). 
Many studies show that public acceptance of GM application is lowest where food or 
animals are involved (Gaskell et al., 2000; Aerni, 2004). The fact that plant applications 
received higher support than animal applications has been reported by a research car-
ried out in the U.S. (Knight, 2006). A FAO global pool reports that 62% of all respondents 
worldwide opposed the application of biotechnology to increase farm animal productivity. 
Another example is a survey performed for the Pew Initiative on Food and Biotechnology, 
which indicates that 65% of consumers disagree with the idea of creating transgenic fish 
to improve efficiency of production (Logar and Pollock, 2005). 
The end-user acceptance of biotech varies considerably by application area and by 
world geography. Medical and pharmaceutical biotechnology related to GM animals is 
generally accepted by most, due to perceived personal benefits for patients carrying strong 
interests and willingness to take high risks. So in the pharmaceutical sector the level of 
acceptance for GM animal applications is higher, ranging from 83% in developing coun-
tries to 70% in Japan (Devlin et al., 2009), because of the expected advantages and the 
different array of political actors (Vàzquez-Salat and Houdebine, 2013). The final user of 
GM animal food-related applications is the consumer. In countries where food security 
is not a priority, consumers acceptance of GM animals is expected to be lower, especially 
for those applications offering economic advantages, like accelerated growth. Only a few 
applications, such as EnviropigTM or pigs with omega-3 fatty acids, offer non-economic 
advantages (Vàzquez-Salat and Houdebine, 2013). Fish biotechnology shows the lowest 
acceptance rate. The low tolerability for GM fish may stem from several factors, including 
environmental concerns. If geographic differences are considered, consumers’ acceptance 
is higher in developing countries where the requirement for enhanced food production 
might be met by application of this technology (Devlin et al., 2009). Different cultural val-
ues were also reported for GM animals resistant to common diseases, such as mastitis. 
318 C. Mora et alii
American animal welfare organisations believed that application of GM would result in 
a welfare improvement for mammals, whilst their European counterparts consider it to 
be an excuse to worsen housing conditions and veterinary interventions, with a negative 
impact on animal welfare (Vàzquez-Salat and Houdebine, 2013). Another study shows 
that disease-resistant animals were the most accepted among livestock-derived prod-
ucts by U.S. consumers, while the least accepted were animals producing tastier and ten-
der meat, those producing human organs for xenotransplantation, and those providing 
increased outputs (Knight, 2006). 
Some empirical studies analyze consumer acceptance of specific GM products, e.g. 
reporting a higher consumer preference of conventional over GM pork (Novoselova et al., 
2005). In this case, the negative perception of GM pork may be compensated by improve-
ments in quality, increased animal health and welfare (Greger, 2011), a lower impact on 
the environment, less residues and a price discount (Novoselova et al., 2005). Increased 
animal welfare has the most positive effect on consumer choices, whereas improvement in 
environments receives the lowest utility. This means that, according to this study, consum-
ers trade off GM applications with significant benefits, included price discount. In other 
words, they have an interest in GM products as long as they bring them different benefits 
and they are substantially cheaper. The amount of monetary compensation is also depend-
ent on GM application (Novoselova et al., 2005).
Price discount is the most quoted personal benefit for accepting GM salmon (Kuznesof 
and Ritson, 1996, Grunert et al., 2001, Bennet et al., 2005). Other benefits associated with 
GM salmon consumption are health benefits, resulted from higher omega-3 intake (Lut-
ter and Tucker, 2002; Qin and Brown, 2006; Smith et al., 2010) and environmental ben-
efits, from reducing the need for chemical usage (Bennet et al., 2005) or using less fodder 
(Grunert et al., 2001). Low consumer acceptance results in high price discounts required 
by consumers to buy GM salmon, or premium price to avoid this product (Kaneko and 
Chern, 2005, Chen and Chern, 2004, Chern and Rickertsen, 2004, Grimsrud et al., 2002). 
Consumer acceptance in the U.S. is higher than in Europe, which leads to a lower price 
discount required than for European consumers (Chern and Rickertsen, 2004). Other 
important factors, like environmental sustainability, human health effects, animal health 
and welfare and ethical concerns may also affect consumer acceptance of GM fish.
In this context, a study conducted within the PEGASUS project analysed 71 papers con-
taining data on public perceptions of agri-food applications of genetic modification (Frewer 
et al., 2013). These papers were published between 1994 and 2010, reporting on data collect-
ed between 1990 and 2008, and were amenable to formal meta-analysis. The results indicate 
that consumer intention to use the products of GM animals was lower than for GM plants 
or for GM applications in general, independent of region. Among Europeans, there was less 
intention to purchase and a lower acceptance for the products derived from GMOs than in 
Asia and North America. Similarly, results show that North American and Asian consumers 
had more positive attitudes to GM applied to agri-food production compared to Europeans. 
North Americans perceived more benefits associated with GM overall when compared to 
Europeans and Asians. However, benefit perception increased with time in all of the regions 
for which analysis was possible. This effect occurred independent of whether the target of 
the application was focused on GM animals, plants or generic applications. North American, 
South American and Asian participants perceived fewer risks than Europeans. Risk percep-
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tion increased with time, almost equally compared to benefit perception increase, independ-
ent of region and of target organism. In contrast, ethical and moral concerns were greater in 
North America and Asia compared to those in Europe. 
3.2 Producers’ acceptance
Like consumers, producers may also have concerns about the adoption of a new tech-
nology. Uncertainty surrounding the way the technology will perform in the future, con-
cerns related to increased dependency on input suppliers, expectations of higher input 
prices, problems related to coexistence at the production stage and segregation along the 
supply chain, uncertainty of the results and of the likely consumer acceptance, are among 
the main producers’ concerns cited in the literature reviewed (Melo et al., 2007; Novoselo-
va et al., 2007; Areal et al., 2012). It is also clear that producer acceptance will depend on 
the benefits expected from the GM application (reduction of feeding costs, increase yields, 
etc.) and on how costs and benefits are distributed across the chain. It is often argued that 
the costs of technology adoption occur in one stage of the chain, while the benefits are 
perceived in another stage (Novoselova et al., 2007).
Initially, the methods for animal transgenesis, such as microinjection technology (i.e. 
DNA transfer via direct microinjection into a pronucleus or cytoplasm of embryo), were 
highly inefficient, but recent scientific advances have overcome many of these technical 
difficulties (Houdebine, 2009). However, it has been suggested that GM animal applica-
tions for food production are more technically difficult to develop than the pharmaceu-
tical ones, mostly because of difficulties in selecting the appropriate target genes and 
because of increased welfare concerns, especially regarding growth-related transgenesis 
(Vàzquez-Salat and Houdebine, 2013). Moreover, the long reproductive cycles of large ani-
mals, such as cows, is considered as a major limiting factor, since projects involving such 
animals require significant investment over extended periods of time (Vàzquez-Salat and 
Houdebine, 2013). Compared to mammals, avian species are easy to raise and have short 
reproductive cycles and high egg production; they are therefore particularly suited to 
more efficient production of commercially valuable and biologically active proteins in egg 
white for pharmaceutical and industrial use (Li and Lu, 2010). Similarly, the high research 
attention placed on transgenic fish is explained by technical factors, i.e., a higher produc-
tion of eggs that can be more easily manipulated (Aerni, 2004), as well as by economic 
reasons, since fish farming is a rapidly growing market (Menozzi et al., 2012). 
It has also been suggested that existing structural differences in different production 
chains will also have an effect in the adoption of GM animals. The strong vertical integra-
tion and the powerful role of multinational companies in sectors like pharmaceuticals may 
facilitate the adoption of a new application (Vàzquez-Salat and Houdebine, 2013). The 
commercial release of transgenic animal products into food chains may also require new 
boundaries, e.g., segregation and other handling measures required to guarantee coexist-
ence (Areal et al., 2012). This implies additional costs on the production chains while also 
creating new objects of governance requiring specific regulatory attention (Bloomfield and 
Doolin, 2011). The production of high-value products from transgenic livestock, e.g. lac-
tose-free milk, could also affect the structure of agricultural industry with new niches and 
segmented markets (Melo et al., 2007).
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In the specific case of aquaculture, it has been suggested that a company that produc-
es a new growth-enhanced salmon may not just face scepticism from consumers, but may 
also be shunned by the fishery industry itself. American aquaculture producers have been 
described as reluctant to accept GM fish, and aquaculture producers’ association in Nor-
way reassured the consumer that they will not use GM salmon in their farms (Vazquez-
Salat and Houdebine, 2012). Established local fish producers might fear new competition 
from transgenic fish and a radical change in the market structure of the sector. If trans-
genic fish become widely grown because of their higher efficiency, and if special brood-
stock are required to produce fry for on-growing to adults, which cannot be used as 
broodstock, a dependency on input suppliers is created. Depending on the arrangements 
made for seed supply, this dependency may become more or less oppressive for fish farm-
ers (Beardmore and Porter, 2003). In turn, retailers, who wield most market power in the 
food business and value consumer concerns more strongly than producers’ innovative 
strategies, may be unwilling to buy transgenic fish and run the risk of being ostracized by 
their customers. Companies may also be afraid of anti-GMO campaigns by activist groups 
which might negatively affect the public image of the brand (Aerni, 2004). 
The picture varies considerably if we consider the pharmaceutical sector. Biopharm-
ing is the production of pharmaceutical compounds in plant and animal tissue in agri-
cultural systems and it is considered as the next major development in both farming and 
pharmaceutical production (Kaye-Blake et al., 2007). For biomedical applications, GM 
animal technology not only enjoys the greatest public acceptance due to perceived per-
sonal benefits – such as obtaining cheaper drugs produced more quickly – overriding 
other ethical concerns (Devlin et al., 2009), but also commands supreme economic incen-
tives. For pharmaceutical firms the use of transgenic animals for producing proteins and 
other pharmaceutical compounds in milk and other animal tissues, promises a method 
for reducing production costs and increasing yields. However, due to the high costs, the 
production of transgenic animals such as pig, goat, sheep and cattle must bring an elevat-
ed profit in order to be an economically feasible investment. Drugs produced by animal 
bioreactors, although highly valuable, are often targeted to a small community of patients 
which makes these applications less attractive to multinational companies’ investment 
(Vàzquez-Salat and Houdebine, 2013). Nonetheless, the production of high-value pharma-
ceutical substances is the principal and most promising application for animal transgen-
esis (Melo et al., 2007). So it is not surprising that the recombinant protein ATryn® 
(human antithrombin-III) produced in transgenic goats’ milk was approved in the EU 
in 2006 (Houdebine, 2009) and the RuconestTM (Rhucin® outside the EU), a recombinant 
C1-inhibitor produced by a GM rabbit, in 2010 (Vàzquez-Salat and Houdebine, 2013). 
3.3 Policy implications
Public policies affect the profitability of private R&D investment through mecha-
nisms that include direct public funding of research, intellectual property rights legisla-
tion, regulatory policies, financial and tax policies, education policies and other policies 
covering the environment and industry (Caswell et al., 2003). Several documents have 
been produced to provide insights into the governance of products derived from trans-
genic animals (Gavin, 2001; Kleter and Kok, 2010). Food safety and environmental risk 
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assessments are considered fundamental steps to deal with these new technology applica-
tions. Recently, a review was carried out on behalf of the European Food Safety Authority 
(EFSA) to define environmental risk assessment criteria for GM fish to be marketed in 
the EU (Cowx et al., 2010). It has also been argued that, as decisions made by one coun-
try may affect the others, different approaches towards decision-making should be harmo-
nized as much as possible (Le Curieux-Belfond et al., 2009).
Intellectual property rights (i.e. patents, trademarks and copyrights) influence a firm’s 
incentive to invest in R&D by enhancing a firm’s ability to capture rent and profits result-
ed from the innovation (Caswell et al., 2003). In the case of biotechnology and transgenic 
animal in particular, this is a very difficult issue. The transgenic animals’ patent debate is 
not confined to technical and legal arguments and has extended over ethical and political 
issues, including public opinion. Many products of nature (like specific antibiotics, micro-
organisms, protein etc.) have been successfully patented protecting the innovators right to 
reproduce. But it is debatable whether a naturally occurring substance can be patentable, 
as it lacks novelty and inventive steps. However, if a product of nature is enriched, puri-
fied or modified in an industrially useful format, it is then patentable. Biological materials 
which previously existed in nature are patentable provided they are purified from their 
natural environment and confirm to the general patentability principles regarding novelty, 
non-obviousness, utility and sufficiency of disclosure (Daneshyar et al., 2006). 
The future of private industry funding for biotechnology R&D will be influenced by 
the regulations in force. For instance, multinational companies in the pharmaceutical 
industry were believed to be unwilling to invest in GM applications until they are accept-
ed by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the 
European Medicines Agency (EMA) (Vàzquez-Salat and Houdebine, 2013). In particular, 
environmental and food safety regulations are expected to affect the profitability of R&D 
by i) increasing the costs of developing new technology by: extending the time neces-
sary to bring a product to market and ii) increasing the cost of meeting stricter standards 
(Caswell et al., 2003). Regulatory policy and industry practices associated with transgenic 
livestock must be transparent and effectively communicated to achieve consumer accept-
ance (Kochhar and Evans, 2007). Strict control of an animal or a herd starts at the level of 
identification. Reliable and permanent identification is already available in the livestock 
industry in many forms, such as ear tags, ear tattoos, external electronic transponders, 
subcutaneous electronic transponders, etc. (Gavin, 2001). Segregation measures along the 
supply chain to guarantee coexistence of GM and non-GM animals and derived products 
may impact producers’ willingness to adopt the technology (Areal et al., 2012). Therefore, 
the impact of heavy regulatory procedures may be stronger in the breeding sector, where 
the abilities of small and medium enterprises to efficiently comply with it can be limited, 
than in the pharmaceutical sector, where the market is highly harmonised and shaped to 
absorb the administrative regulatory burden (Vàzquez-Salat and Houdebine, 2013). 
Labelling and information policies could be a solution in helping consumers to make 
a deliberate choice and in helping producers to differentiate their products. Assuming that 
GM animals and derived products will be properly labelled in the EU once approved and 
commercially available, it is unclear whether the food obtained from GM animals will 
have to be labelled on other markets. The U.S. FDA is now debating whether GM salmon 
should be labelled (U.S. Food and Drug Administration, 2010), mostly for environmen-
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tal and allergenicity reasons, although this would lead to a different solution compared to 
food from GM crops. Labelling regulations will lead to extra costs, including the costs of 
traceability (Novoselova et al., 2007). Monetary costs associated with tracing and labelling 
biotech-derived animals and their products have to be taken into account, especially in 
countries like U.S. where such regulations are not in force for GM crops. Other costs that 
might be necessary to meet the regulatory requirements (e.g., segregation with physical 
containment for GM fish) will also have to be considered. The costs of complying with 
regulations will likely reduce the private profitability of the technology, but the public will 
benefit from reduced risk. Thus, the balance between the costs and benefits of the regula-
tion will determine the social cost-effectiveness of the regulation (Caswell et al., 2003). 
Finally, it has been argued that GM animals will likely face similar regulatory chal-
lenges in the U.S. and EU for their strict regulations in both pharmaceutical and food sec-
tors. However, it is not clear yet if these regulations will also be applied in other countries 
where investment is high (e.g., Argentina and China), or if a more favourable regulatory 
framework will offer a competitive advantage (Vàzquez-Salat and Houdebine, 2013). In 
this context, China, where regulatory requirements for the approval of GM animals and 
derived products are already in place, is expected to take the lead thanks to a favourable 
policy environment and steady investments in this field. 
4. Life science factors affecting the adoption of GM animals
As explained above, the PEGASUS project also explored the factors of GM animals 
producing food, feed or pharmaceuticals which have an advantageous or disadvanta-
geous impact from a life science perspective. The outcomes were summarized in a pro-
ject report (Kostov et al., 2011). From a general, overall review of the literature and risk 
assessment guidance documents [including the Codex alimentarius and scientific panels 
of the European Food Safety Authority (EFSA)], different categories of factors were iden-
tified. These were human health, animal health and welfare, the environment, sustainabil-
ity and agro-biodiversity. 
Human health considerations include the potential effects on consumers of GM 
animal-derived foods as well as humans, such as farmers, coming into contact with the 
animals. For the safety of foods produced from GM animals, internationally harmonized 
guidelines have been published by the FAO/WHO Codex alimentarius (Codex alimenta-
rius, 2009). This is an international organization representing nations of the world which 
sets internationally recognized standards and codes of conduct for food quality and safety. 
The scientific panels of EFSA on genetically modified organisms and on animal health and 
welfare recently published guidance on the assessment of food and feed safety as well as 
animal health and welfare, which expands upon the Codex alimentarius’ (EFSA, 2012). A 
central role in the approach recommended by Codex alimentarius and the EFSA GMO 
Panel is the comparative assessment of GM products with conventional non-GM coun-
terparts with a history of safe use, in addition to the molecular characterization of the 
introduced genetic material. The focus of the additional tests is on the differences iden-
tified by this comparative analysis. Commonly considered items include the occurrence 
of unintended effects alongside targeted modification, potential toxicity and allergenicity 
(of the introduced or altered components), nutritional value, and horizontal gene transfer. 
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Additional considerations include, for example, the potential transfer of zoonotic patho-
gens from the animal (acting as a reservoir) to humans and the safety of the vectors used 
for the transformation of the GM animal (e.g. viruses) (Codex alimentarius, 2009; EFSA, 
2012). Among the advantages identified are the ability to produce enhanced quantities 
of food (food security) or food with increased quality characteristics, as well as new or 
ameliorated pharmaceuticals for the cure of patients. As a disadvantage, potential human 
health impacts linked to the use of this technology have to be assessed before the product 
can be marketed (Kostov et al., 2011).
The impact on the health and welfare of the GM animals themselves are also a focus 
of attention. This includes the health of founder animals, selected further for desirable 
traits and absence of other adverse symptoms and used for commercial production as well 
as the first generations after genetic modification. The approach is comparative in this case 
too, and compares the impact of the genetic modification of the GM animal versus the 
health and welfare of non-GM animals. Moreover, health and other phenotypic charac-
teristics of the GM animal compared to a non-GM animal may also serve as an important 
indicator for potential adverse effects on both consumers and people coming into contact 
with the animal. Welfare includes the ability of the animal to express its normal behaviour, 
among other things, and is linked to animal health. An advantage of the use of GM tech-
nology in animals is the ability to enhance resistance against parasites and diseases, while 
the disadvantages include possible suffering of the animals during the genetic modifica-
tion process (including that of surrogate dams) as well as potentially adverse effects on the 
offspring (Kostov et al., 2011).
The potential environmental impact of GM animals straddles a wide range of issues, 
of which two important ones are 1) the possible effects on wild populations, such as intro-
gression or replacement (once the GM animal is released into the environment) and 2) 
the impact on the eco-system as a whole. These effects can be caused by either or both 
of two factors; the behaviour of the GM animal itself once released into the environment 
(e.g. after escape) and the production systems used for raising the GM animal as com-
pared to conventional systems. The possible advantages identified include the decreased 
environmental burden of more efficient production systems as well as diminished require-
ments for space and inputs (e.g. for rapidly growing farmed fish). The possible disadvan-
tages identified include possible disruption of ecosystems and loss of biodiversity of wild 
populations (Kostov et al., 2011).
With regard to the issues of sustainability, this relates to the ecological footprint of the 
production system for raising the GM animal (and whether this has changed as compared 
to conventional production). Agro-biodiversity relates to the animal breeds that are availa-
ble to breeders for creating new breeds with desirable characteristics. A possible advantage 
of GM animals in this respect is that this technology widens the genetic resources avail-
able to the breeders for improvement of animal characteristics (such as disease resistance). 
On the other hand, there may be a loss of agro-biodiversity of commercially used breeds 
(e.g., if less competitive than GM animals) as well as issues related to the privatization of 
genetic resources (e.g., patenting) (Kostov et al., 2011).
The advantages and disadvantages from life science perspectives have been further 
explored in depth in three case studies, growth-enhanced salmon, dairy cattle produc-
ing human lactoferrin through their milk, and rabbits producing humanized polyclonal 
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antibodies. These case studies include aspects of terrestrial and aquatic animals, as well as 
food and pharmaceutical applications (Kostov et al., 2011).
Growth-enhanced GM salmon, which is to be used in aquaculture, does not grow 
bigger than conventional cultured salmon but reaches its marketable size within a short-
er time span. The possible advantages identified include nutritional benefits for consum-
ers if fish becomes more affordable and hence is consumed in greater amounts by certain 
segments of the population (leading to increased uptake of omega-3 fatty acids). Another 
envisaged advantage is decreased environmental burden caused by aquaculture systems 
employing GM fish owing to less feed inputs required and less waste for the same outputs. 
Possible disadvantages are animal health issues, such as skeletal deformations observed in 
some studies on experimental GM fishes and enhanced stress under oxygen-deprived con-
ditions caused by increased need for oxygen. An environmental issue, and a possible dis-
advantage, which has received a lot of attention surrounding the potential market intro-
duction of growth-enhanced salmon, is the effect of escape of such fish into the wild on 
natural salmon populations. Because of this, one company seeking market approval in the 
USA has proposed to grow this salmon in tanks in land-locked facilities instead of the 
conventional aquaculture practice employing pens in open waters (Kostov et al., 2011).
With regard to the recombinant human lactoferrin protein (naturally occurring in 
human mother’s milk) produced through the milk of GM dairy cattle, it is noted that this 
product may have different purposes. For example, lactoferrin’s antibacterial properties 
may strengthen the animal’s defence against certain bacterial infections, such as mastitis. 
Because of its antibacterial properties, it may also find applications in human medicine, 
after purification from the bovine milk. Moreover, because of its iron-binding capaci-
ties, the bovine form of lactoferrin has been used as an ingredient for baby and infant 
foods. The human version of this protein could help consumers to avoid allergic reactions. 
Depending on the application chosen, the products could thus fall under different cate-
gories, each covered by a different legislation (besides GMO regulations), such as dietary 
supplements, human or veterinary medicine, or foods for medicinal or particular nutri-
tional uses. A possible advantage of the GM dairy cattle producing recombinant human 
lactoferrin is the improved health of humans and animals, while possible disadvantages 
include animal health and welfare effects on the first generation of offspring and their 
dams (so-called “large offspring syndrome”, which may occur at high frequencies as a 
result of cloning techniques for creating the GM animals) (Kostov et al., 2011).
With regard to the production of humanized polyclonal antibodies in rabbits, this 
aims at the application of antibodies for “passive immunization” of human subjects against 
the antigens, such as pathogens, with which the rabbits have been challenged so as to 
trigger the production of antibodies neutralizing the antigen. These antibodies contain a 
range of molecules with slightly different structures that recognize distinct parts on the 
antigen, to which they bind, forming an antibody-antigen complex that can be further 
neutralized by specialized cells of the host’s immune system. Replacing the rabbit’s own 
polyclonal antibodies with a humanized version helps to prevent possible reactions against 
rabbit-derived proteins when antibodies purified from serum of immunized GM rabbits 
are used in human subjects. A wide range of antigens can be used to challenge the GM 
rabbits so as to trigger the production of antibodies recognizing these antigens. This pro-
vides a flexible production platform that can be employed against a great variety of dis-
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eases to be treated with passive immunization, and is also envisaged as a possible advan-
tage for human health. A possible disadvantage is the environmental consequences of a 
hypothetical escape of these animals into the wild. It is considered that GM animals used 
for production of pharmaceuticals will have to be kept in highly contained facilities under 
disease-free conditions, so that the animals would be unlikely to be able to cope with nat-
ural conditions in the hypothetical event of escape (Kostov et al., 2011).
The case studies above show that a number of generalizations are possible on poten-
tial issues relating to food and feed safety, animal health and welfare, environmental safe-
ty, sustainability and agro-biodiversity. But at the same time each specific case also raised 
case-specific concerns and envisaged benefits from the life-science perspective.
5. Conclusions
The production of transgenic animals, which could potentially have a big impact on 
the livestock and pharmaceutical chains, has proceeded much slower than genetic modifi-
cation of crops. Improvements in animal biotechnology are expected to result in economic 
benefits for farmers, processors and consumers. Beside the direct economic effects, other 
externalities, both positive and negative, should be considered in the overall evaluation. 
The interest in GM development in aquaculture is stronger than for terrestrial ani-
mals. There are several reasons for this; faster growth rates in fish and improved feed 
conversion rates that may result in a cost reduction, and thus lower market prices, which 
also explain why the economic impact of the introduction of GM fish could be signifi-
cant. The case of growth-enhanced GM fish shows that benefits for producers, arising 
from increased growth rates and food conversion rates, may lead to a reduction in costs 
and, without a full transmission of these advantages to consumers, to an increase in gross 
margin. At the same time, environmental and human health risks should be considered in 
depth in the overall evaluation of the transgenic fish introduction. In fact, serious ecologi-
cal concerns associated with GM fish farming may make necessary physical containment 
strategies, which may potentially limit the economic attractiveness of GM fish.
Biopharming is a new territory for the agricultural and pharmaceutical industries, and 
presents novel challenges for government regulators and others. Due to the high cost, the 
production of transgenic animals such as pig, goat, sheep and cattle must bring an elevat-
ed profit in order to be a feasible economic investment. For this reason, the production 
of high-value pharmaceutical substances, which correspond to a market worth billions of 
dollars, is currently the principal and most promising application for animal transgenesis. 
However, the financial commitment required during the protracted development phase 
has halted many attempts at commercial exploitation and, at present, only two drugs pro-
duced in this way have reached the market. 
Given the rapid development of these technologies and the intense GM debate of the 
1990s, some governments are beginning to produce a regulatory response to the market-
ing of GM animals. Experts argue that the distinction between the U.S. and EU approach-
es, which in the past accompanied the development of GM crops, might be less marked 
in the case of GM animals (Vàzquez-Salat et al., 2012). Both players are going to face 
stakeholders’ adversity, e.g. from animal welfare organizations, and a lower positive pres-
sure from multinational companies. The regulatory strategy adopted by these global play-
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ers will affect their ability to exploit the commercial potential of biotechnologies as well 
as international trade. In this context international bodies, such as FAO, World Health 
Organization (WHO) and World Organization for Animal Health (OIE), will have an 
important role in providing forums for neutral discussion and encouraging harmonization 
in the food sector (Vàzquez-Salat et al., 2012).
A review of these issues in general and for the three case studies in particular (growth-
enhanced salmon, dairy cattle producing recombinant human lactoferrin, rabbits produc-
ing humanized polyclonal antibodies) shows that at present it is not possible to make gen-
eralizations on the possible advantages and disadvantages of GM animals from a life sci-
ence perspective. So should one of these be introduced for possible marketing in Europe, a 
case-by-case approach will need to be followed for the assessment of these issues. 
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